Veritable’s BioMarin Pharmaceuticals BMRN Stock Holding History

Veritable’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,073	Closed	-$256K	–	745
2020 Q2	$256K	Buy	+2,073	New	+$206K	0.01%	634
2020 Q1	–	Sell	-2,540	Closed	-$215K	–	741
2019 Q4	$215K	Buy	+2,540	New	+$192K	﹤0.01%	769
2019 Q2	–	Sell	-2,493	Closed	-$221K	–	805
2019 Q1	$221K	Buy	+2,493	New	+$231K	﹤0.01%	730
2018 Q4	–	Sell	-2,205	Closed	-$214K	–	781
2018 Q3	$214K	Buy	2,205 +29	+1%	+$2.9K	﹤0.01%	765
2018 Q2	$205K	Buy	+2,176	New	+$191K	﹤0.01%	757
2018 Q1	–	Sell	-3,555	Closed	-$317K	–	802
2017 Q4	$317K	Buy	+3,555	New	+$309K	0.01%	616
2016 Q4	–	Sell	-2,267	Closed	-$210K	–	740
2016 Q3	$210K	Buy	+2,267	New	+$213K	0.01%	680
2016 Q1	–	Sell	-1,964	Closed	-$206K	–	709
2015 Q4	$206K	Buy	+1,964	New	+$205K	0.01%	682
2015 Q3	–	Sell	-1,618	Closed	-$221K	–	719
2015 Q2	$221K	Sell	1,618 -10,601	-87%	-$1.31M	0.01%	663
2015 Q1	$1.52M	Buy	12,219 +510	+4%	+$54K	0.03%	308
2014 Q4	$1.06M	Buy	11,709 +1,220	+12%	+$101K	0.02%	396
2014 Q3	$757K	Buy	10,489 +424	+4%	+$27.9K	0.02%	484
2014 Q2	$626K	Buy	10,065 +2,120	+27%	+$128K	0.01%	536
2014 Q1	$542K	Hold	7,945	–	–	0.01%	567
2013 Q4	$559K	Hold	7,945	–	–	0.01%	548
2013 Q3	$573K	Sell	7,945 -3,190	-29%	-$212K	0.01%	530
2013 Q2	$621K	Buy	+11,135	New	+$694K	0.01%	511

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Veritable's BMRN Position: Q3 2020 in Review

Veritable sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 2,073 shares — an estimated $256K sold.

Veritable first reported a position in BMRN in Q2 2013 and held it in 17 quarters. The position peaked at $1.52M in Q1 2015. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

Veritable reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Veritable sold 2,073 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $256K.
Veritable first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Veritable's BioMarin Pharmaceuticals position peaked at $1.52M in Q1 2015.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Veritable's 13F filing for Q3 2020, filed 13 Nov 2020.